« Back
Home /
Nelarabine

Nelarabine

Item no.	S1213-5
Manufacturer	Selleckchem
CASRN	121032-29-9
Amount	5 mg
Quantity options	10 mg 100 mg 1 g 10 g 10 mM/1 mL 200 mg 25 mg 5 mg 50 mg 5 g
Category	Oncology Food Safety Drugs Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Smiles	COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	506U78,Arranon
Similar products	Nelarabine
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	297, 27
Administration	Administered via i.v.
Animal Models	Healthy adult male rhesus monkeys
Cell lines	HSB2, ALL-SIL, JURKAT and PER-255 cell lines
Clinical Trials	Nelarabine plus Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Methotrexate or Vincristine has entered in a phase II clinical trial in the treatment of leukemia, acute lymphoblastic leukemia, and lymphoblastic lymphoma.
Concentrations	0.125 ug/mL - 8 ug/mL
Dosages	35 mg/kg
Formulation	Control
IC50	0.13 ug/mL, 0.13 ug/mL, 0.13 ug/mL, 0.13 ug/mL, 0.13 ug/mL, 0.13 ug/mL
In vitro	The IC50 of Nelarabine is 25-fold and 113-fold higher than ARAC in T- and B-lineage, respectively. T-ALL cells are eightfold more sensitive to Nelarabine than B-lineage but there is considerable overlap. The efficacy of NEL in T-lineage and B-lineage cell lines is 25-fold and 113-fold less than ARAC, respectively. [1] Nelarabine acts by inhibiting DNA synthesis and inducing apoptosis in susceptible cells. [2]Nelarabine demonstrated significant antineoplastic activity with acceptable toxicity. [3]
In vivo	The Nelarabine plasma AUC is 2.82 mM minutes and the ara-G plasma AUC is 20 mM minutes. The terminal half-life of Nelarabine in plasma is 25 min, clearance is 42 mL/minutes/kg, and central volume of distribution is 1.1 L/kg. The terminal half-life of ara-G in plasma is 182 minutes and the central volume of distribution is 1.4 L/kg. In CSF the terminal half-life of Nelarabine is 77 minutes and of ara-G is 232 minutes. The AUCcsf:AUCplasma is 29 % for Nelarabine and 23 % for ara-G. Nelarabine and ara-G do not accumulate with daily infusions because of their relatively short half-lives. [4]
Incubation Time	96 hours
Method	HSB2, ALL-SIL, JURKAT and PER-255 cell lines are tested for drug resistance using the MTT assay. Nelarabine are incubated over 4 days, with concentration tested in triplicate. The IC50 (drug concentration that inhibits cell growth by 50%) is used as the measure of drug resistance. Data represent the average of 2â€“6 experiments performed on separate occasions. In cases where 50% cytotoxicity is not achieved by even the highest dose in a particular experiment, the IC50 is recorded as double the highest concentration tested.
Solubility (25C)	DMSO 60 mg/mL, Water 3 mg/mL, Ethanol <1 mg/mL
Information	Nelarabine (506U78, Arranon) is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells.
Features	Nelarabine is rapidly converted into ara-G through demethoxylation by adenosine deaminase.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S1213-5-datasheet.pdf

S1213-5-safety-datasheet.pdf